Viewing nowNerica Capsule 75mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Dong-A ST Co., Ltd.

MFDS item code 201109231 · Approved 2011.10.27 · Insurance code 642506710
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It also serves as an adjunct to help control partial seizures in patients with epilepsy. In particular, it is effective in alleviating symptoms of fibromyalgia. It is widely used to improve symptoms related to pain and neurological disorders.
This medication is administered orally, regardless of food, with the total daily dose of pregabalin divided into 2 doses. Because this medication is eliminated primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is eliminated primarily by the kidneys as unchanged drug. Because the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25 (mg), 100 (mg), single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: Supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This drug may increase the risk of suicidal thoughts or behaviors; therefore, if depressive symptoms or mood changes occur during treatment, it is important to consult medical personnel immediately. Patients with hypersensitivity to this drug or genetic issues such as lactose intolerance should not take it. Diabetic patients should be careful as weight gain may necessitate dose adjustments of blood sugar control medications. If severe allergic reactions such as angioedema occur, the medication should be discontinued immediately, and medical personnel notified. Elderly patients may be at increased risk of falls due to dizziness or drowsiness, so caution is especially advised during the initial phase of treatment. Blurred vision or changes in vision may occur; if these symptoms appear, advice from medical personnel should be sought. Sudden discontinuation of this medication may cause withdrawal symptoms such as insomnia, headache, and anxiety, so the dose should be gradually reduced according to medical advice. Patients with a history of substance abuse may be at risk of misuse of this medication and should be monitored closely while taking it. Patients with impaired kidney function may require dose adjustments. Patients with heart disease should consult medical personnel before taking this medication. When taken with opioid analgesics, the central nervous system depressant effects may be increased; thus, caution is required when used in combination. Patients with impaired respiratory function or elderly patients may have a higher risk of severe respiratory depression and may require dose adjustments. During early pregnancy, there is a risk of fetal malformations; therefore, women who are pregnant or planning to become pregnant should consult with medical personnel before taking this medication and use effective contraception. Nursing mothers should consult with medical personnel about whether to take this medication since it may be passed into breast milk. This medication can cause dizziness and drowsiness; therefore, patients should avoid dangerous activities such as driving or operating machinery after taking it. Severe skin responses such as Stevens-Johnson syndrome may rarely occur; if skin abnormalities develop, the medication should be stopped immediately and medical personnel notified. In case of overdose, confusion, drowsiness, and seizures may occur, and blood dialysis may be required if necessary. This medicine must be kept out of the reach of children and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The ideal storage temperature is between 1 degree and 30 degrees Celsius.
This medicine is a hard capsule with a reddish-brown upper part and a white lower part containing white powder that appears white or light yellow.
30 capsules/bottle, 300 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Dong-A ST Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.